We are really sitting at a low after that little excitable mini run which was premised upon passing a key scientific acceptance due diligence milestone with the pharma partner. They have gone to the next stage which involves hammering out the specific numbers and conclusion of an agreement. It's unbelievable they have made it through that hurdle, which is arguably the toughest one, and its also unbelievable that we are still trading at 20-23 cents....
Look, if a big pharma decides to engage their business development arm, that means something, and in my view, something serious. Pay attention people. This is out of Howards hands, if that gives you any comfort.
If you really look hard at the five year chart and combine that with the future clear probable (not guaranteed) path to a global deal, one can only draw one conclusion, and that is up. Might bob up and down for a bit, if you are thinking of getting in, buy the lows for as long as they last.
They said solid news flow to come in the months to come and in addition to a global deal for 1067 and sglt2 diabetic treatment for pets on the radar, I predict that there will also be other newsworthy items on the other key pipelines as some have followed. The combination of all these items would certainly put us in sustainable new territory.